Orbit Discovery, a provider of peptide discovery services based in the UK, has extended its research collaboration with Evergreen Theragnostics, a radiopharmaceutical company focused on precision medicine.

Having initially signed an agreement initially in April 2023, the companies will further extend research on novel targeting peptides for the treatment of cancerous diseases. This will be achieved through the utilisation of Orbit Discovery’s screening platform to identify and optimise peptide candidates, along with Evergreen Theragnostics knowledge of radiopharma development and its translation to a clinical setting.